Back to the Top
The following message was posted to: PharmPK
Dear All,
While reporting bioavailability of any prodrug, is it to be
reported for prodrug as such or for the active moiety resulting
from conversion of that prodrug in vivo?
Thank you,
Regards,
Satyawan
Back to the Top
The following message was posted to: PharmPK
hello,
my point of view is that: as you are interested in the active moiety
parameters you should report the active moiety's bioavailability. The
dosed substance is the prodrug that should be defined in active
equivalent and the substance present in the blood compartment is the
active.
Hope this helps.
Regards,
Frederic
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)